2月28日,国家药品监督管理局发布公告,上海济煜医药科技股份有限公司自主研发的 1 类抗肿瘤创新药济乐美@(硫酸索西美雷塞片)获批上市,主要用于治疗至少接受过一种系统性治疗的鼠类肉瘤病毒癌基因KRAS G12C突变型的晚期非小细胞肺癌(NSCLC)成人患者,为晚期非小细胞肺癌患者带来治疗新选择。值得注意的是,该项目是太美医疗科技独立评审中心(IRC)助力获批的第 60 个项目,再度彰显其在临床研究...
Source Link2月28日,国家药品监督管理局发布公告,上海济煜医药科技股份有限公司自主研发的 1 类抗肿瘤创新药济乐美@(硫酸索西美雷塞片)获批上市,主要用于治疗至少接受过一种系统性治疗的鼠类肉瘤病毒癌基因KRAS G12C突变型的晚期非小细胞肺癌(NSCLC)成人患者,为晚期非小细胞肺癌患者带来治疗新选择。值得注意的是,该项目是太美医疗科技独立评审中心(IRC)助力获批的第 60 个项目,再度彰显其在临床研究...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.